Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 2

Conditions

Breast Neoplasms 13Prostatic Neoplasms 9Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Endometrial Neoplasms 3Colorectal Neoplasms 3Cardiovascular Diseases 3Cardiotoxicity 3Triple Negative Breast Neoplasms 2Polycystic Ovary Syndrome 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Kidney Neoplasms 2Heart Failure 2Endometrial Hyperplasia 2Carcinoma, Renal Cell 2Waldenstrom Macroglobulinemia 1Venous Thrombosis 1Urogenital Neoplasms 1Smoking 1Sarcoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Overall Survival 1Ototoxicity 1

Interventions

Cyclophosphamide 184fludarabine phosphate 162fludarabine 128Busulfan 116Tacrolimus 109Mycophenolic Acid 101Whole-Body Irradiation 97Antilymphocyte Serum 87Peripheral Blood Stem Cell Transplantation 84Azacitidine 82Melphalan 81Filgrastim 74Cytarabine 74Cyclosporine 72Methotrexate 64Decitabine 57Granulocyte Colony-Stimulating Factor 51Thiotepa 45Radiotherapy 41thymoglobulin 40Stem Cell Transplantation 40Cord Blood Stem Cell Transplantation 40venetoclax 39Clofarabine 35Sirolimus 30Methylprednisolone 30Specimen Handling 27Etoposide 24Alemtuzumab 24Biopsy 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Myelodysplastic Syndromes × Atorvastatin × Clear all
NCT03560882 2026-05-06

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

University of Kansas Medical Center

Phase 1 Active not recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03066466 2021-04-27

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

Loyola University

Phase 3 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01491958 2018-01-23

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
40 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡